Evidence map›Paper›PMID 42453191›Full record

ArticleNeuro-oncology practice2026

Patient perspectives on diagnostic uncertainty and novel diagnostic tests in neuro-oncology.

Veerle J Ruijters, Marloes M Bauer, Nelleke Tolboom, Tatjana Seute, Leonie N C Visser, Tom J Snijders

Abstract read
In one paragraph

Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Veerle J RuijtersDepartment of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands.
Marloes M BauerDepartment of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.
Nelleke TolboomDepartment of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-8005-2833
Tatjana SeuteDepartment of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-3668-6177
Leonie N C VisserJulius Center, Department of Bioethics and Health Humanities, UMC Utrecht, Utrecht, The Netherlands.
Tom J SnijdersDepartment of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0003-0857-081X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the follow-up of glioma patients, differentiating treatment-associated changes from tumor progression on MRI is challenging. In the Netherlands, this diagnostic uncertainty often leads to watchful waiting, delayed treatment, and patient distress. So far, research on new diagnostic tests has primarily focused on accuracy, while patient perspectives remain largely unexplored. This qualitative study aimed to explore glioma patients' perspectives on diagnostic uncertainty and the implementation of tests aimed at reducing uncertainty. Methods: Semi-structured interviews were conducted with 10 diffuse glioma patients (31-70 years old; 50% female) treated at UMC Utrecht, the Netherlands. Two independent coders analyzed interview transcripts thematically to identify key themes in patient perspectives. Results: Four themes were found: (1) Most patients experienced diagnostic uncertainty, which was stressful for themselves and their loved ones. (2) A new test was considered meaningful if it provided early certainty. Patients wanted certainty to guide treatment, and even without therapeutic options, a certain diagnosis could optimize quality of life by living more consciously. (3) All patients wished to participate in decision-making regarding undergoing new tests, with variable preferences regarding the amount of information to be received. (4) Patients expressed the need for continuity of care, honest communication, and immediate disclosure of test results. Conclusion: Patients value faster certainty from new diagnostic tests, both to guide treatment for improved survival and quality of life and to optimize quality of life when no therapeutic options remain. Integrating this emphasis on quality of life into diagnostic research may stimulate patient-centered test implementation, ultimately improving neuro-oncological care.

Indexed as

diagnostic testsdiagnostic uncertaintygliomapatient perspectivesquality of life

Identifiers

PMID42453191
PMCPMC13365155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.